Department of Pediatrics, College of Korean Medicine, Semyung University, Jecheon 27136, Republic of Korea.
RnBS Corp., Seoul 06032, Republic of Korea.
Nutrients. 2022 Dec 21;15(1):28. doi: 10.3390/nu15010028.
This double-blind, randomized clinical trial aimed to evaluate the efficacy and safety of B-3 (BB-3) for reducing body fat. Healthy individuals were randomized into the BB-3 or placebo group (1:1). Dual-energy X-ray absorptiometry was used to evaluate body fat reduction objectively. In the BB-3 group, body weight was lower than before BB-3 ingestion. Regarding waist circumference, hip circumference, and waist/hip circumference ratio, waist circumference and hip circumference were lower in the BB-3 group than in the placebo group at 12 weeks; the waist/hip circumference ratio was found to decrease at each visit in the BB-3 group, although there was no significant difference in the amount of change after 12 weeks. BB-3 did not cause any severe adverse reactions. Body fat was significantly lower in the BB-3 group than in the placebo group. In conclusion, ingesting BB-3 significantly reduces body weight, waist circumference, and hip circumference. Thus, BB-3 is safe and effective for reducing body fat.
这项双盲、随机临床试验旨在评估 B-3（BB-3）在减少体脂肪方面的疗效和安全性。健康个体被随机分为 BB-3 组或安慰剂组（1:1）。双能 X 射线吸收法用于客观评估体脂减少。在 BB-3 组中，体重低于 BB-3 摄入前。关于腰围、臀围和腰臀比，12 周时 BB-3 组的腰围和臀围均低于安慰剂组；BB-3 组在每次就诊时的腰臀比均下降，尽管 12 周后变化量无显著差异。BB-3 未引起任何严重不良反应。BB-3 组的体脂明显低于安慰剂组。总之，摄入 BB-3 可显著降低体重、腰围和臀围。因此，BB-3 安全有效，可减少体脂肪。
